Detalhe da pesquisa
1.
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Lung Cancer
; 173: 83-93, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36162227